Payment overview · 2025
General Payments
$106.73
7 reported records · 4 companies
Healthcare provider profile · identity verified
Daniel S. Senft, DO
Allopathic & Osteopathic Physicians|Family Medicine · LINCOLNTON, NC · NPI 1437175890
Verified facts
What the public records show
CMS Open Payments records show Daniel S. Senft, DO received $106.73 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.64 | 38.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.20 | 36.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.36 | 16.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.53 | 8.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.73 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.53 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 736 | 181 |
| Omeprazole | Omeprazole | 660 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 125 |
| Gabapentin | Gabapentin | 570 | 132 |
| Lisinopril | Lisinopril | 566 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 363 | 96 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 357 | 100 |
| Tramadol Hcl | Tramadol Hcl | 353 | 71 |
| Furosemide | Furosemide | 351 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 335 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 334 | 74 |
| Montelukast Sodium | Montelukast Sodium | 322 | 73 |
| Meloxicam | Meloxicam | 310 | 92 |
| Fluticasone Propionate | Fluticasone Propionate | 307 | 132 |
| Tizanidine Hcl | Tizanidine Hcl | 301 | 91 |
| Potassium Chloride | Potassium Chloride | 297 | 72 |
| Metformin Hcl | Metformin Hcl | 290 | 66 |
| Lorazepam | Lorazepam | 289 | 54 |
| Losartan Potassium | Losartan Potassium | 234 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 67 |
| Trazodone Hcl | Trazodone Hcl | 216 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 48 |
| Simvastatin | Simvastatin | 195 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 183 | 37 |
| Alprazolam | Alprazolam | 178 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 34 |
| Methylprednisolone | Methylprednisolone | 164 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 49 |
| Allopurinol | Allopurinol | 159 | 26 |
| Metformin Hcl Er | Metformin Hcl | 153 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 38 |
| Famotidine | Famotidine | 144 | 36 |
| Diazepam | Diazepam | 137 | 25 |
| Jardiance | Empagliflozin | 133 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 39 |
| Clonazepam | Clonazepam | 130 | 25 |
| Eliquis | Apixaban | 128 | 26 |
| Sucralfate | Sucralfate | 125 | 41 |
| Celecoxib | Celecoxib | 124 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 31 |
| Sertraline Hcl | Sertraline Hcl | 121 | 29 |
| Carvedilol | Carvedilol | 119 | 28 |
| Bupropion Xl | Bupropion Hcl | 117 | 25 |
| Pregabalin | Pregabalin | 113 | 24 |
| Estradiol | Estradiol | 107 | 21 |
| Ozempic | Semaglutide | 107 | 21 |
| Prednisone | Prednisone | 103 | 62 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 102 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 31 |
| Lovastatin | Lovastatin | 100 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 27 |
| Finasteride | Finasteride | 93 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 17 |
| Memantine Hcl | Memantine Hcl | 81 | 18 |
| Warfarin Sodium | Warfarin Sodium | 80 | 11 |
| Levofloxacin | Levofloxacin | 78 | 67 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 20 |
| Benazepril Hcl | Benazepril Hcl | 75 | 18 |
| Amoxicillin | Amoxicillin | 74 | 64 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 73 | suppressed |
| Ondansetron Odt | Ondansetron | 73 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 14 |
| Glimepiride | Glimepiride | 71 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 17 |
| Ibuprofen | Ibuprofen | 68 | 21 |
| Promethazine Hcl | Promethazine Hcl | 66 | 17 |
| Cephalexin | Cephalexin | 64 | 56 |
| Ezetimibe | Ezetimibe | 62 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 14 |
| Nystatin | Nystatin | 58 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 12 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | 17 |
| Mirtazapine | Mirtazapine | 54 | 19 |
| Buspirone Hcl | Buspirone Hcl | 51 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 22 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 14 |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Fluconazole | Fluconazole | 45 | 34 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Ketoconazole | Ketoconazole | 43 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Colchicine | Colchicine | 41 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Atenolol | Atenolol | 38 | 11 |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 28 |
| Azelastine Hcl | Azelastine Hcl | 35 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 16 |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 28 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 19 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 16 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Topiramate | Topiramate | 24 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 12 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 15 |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.73 · 7 records | Novo Nordisk Inc | AREXVY, BEXSERO, BREZTRI, SHINGRIX, VOQUEZNA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error